Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02354131 | Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer | PHASE1 | COMPLETED | 108 | — | — | Feb 15, 2015 | Dec 15, 2021 | Aug 30, 2022 | 2 | United States, Denmark |
This is pick the winer trial. The best arm will be used for phase 3 trial against standard of care.
| Arm | Type | Description |
|---|---|---|
| Niraparib monotherapy | EXPERIMENTAL | Niraparib mono therapy until progression |
| Niraparib-bevacizumab combination | EXPERIMENTAL | Niraparib-bevacizumab combination therapy until progression |
| Name | Type | Description |
|---|---|---|
| Niraparib | DRUG | Niraparib versus Bevacizumab-Niraparib combo |
| Bevacizumab | DRUG | - |
Inclusion Criteria: A patient will be eligible for inclusion only if all of the following criteria are fulfilled: 1. Recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer (platinum sensitivity defined as no recurrence within 6 months of last receipt of platinum/chem...